A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Status:
NOT_YET_RECRUITING
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for a minimum of 120 weeks. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.